Completed PHASE2 INTERVENTIONAL 1-arm NCT05858177

The Efficacy and Safety of Temozolomide in Patients With MPPGL (MPPGL)

The Efficacy and Safety of Temozolomide in Patients With Metastatic Pheochromocytoma or Paraganglioma

Sponsor: Peking Union Medical College Hospital

Conditions Paraganglioma, Malignant Pheochromocytoma Malignant Pheochromocytoma, Metastatic

Updated 3 times since 2023 Last updated: May 4, 2023 Started: Oct 1, 2019 Primary completion: Oct 1, 2022 Completion: Jan 1, 2023

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05858177, this PHASE2 trial focuses on Paraganglioma, Malignant and Pheochromocytoma Malignant and remains completed. Sponsored by Peking Union Medical College Hospital, it has been updated 3 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

3 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jun 2023 — Jul 2024 [monthly]

Completed PHASE2

First recorded

Oct 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Peking Union Medical College Hospital

Data source: Peking Union Medical College Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China